Skeletalis develops precision medicines targeting bone loss to treat osteoporosis and prevent fractures safely.
Skeletalis has raised $8.0M in total funding. The most recent round was Seed. The last funding was announced in November 2025.
Skeletalis's investors include KdT Ventures, Pillar VC, age1, Slocum Wealth Management.
Skeletalis is headquartered in Boston, United States.
Skeletalis develops precision medicines targeting bone loss to treat osteoporosis and prevent fractures safely.
Skeletalis is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Skeletalis — Funding & Investors." VCBacked, November 17, 2025, https://www.vcbacked.co/company/skeletalis. Accessed September 15, 2026.
VCBacked. (2025). Skeletalis — Funding & Investors. Retrieved September 15, 2026, from https://www.vcbacked.co/company/skeletalis
{{cite web |title=Skeletalis — Funding & Investors |url=https://www.vcbacked.co/company/skeletalis |website=VCBacked |access-date=September 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated